.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Cipla
Argus Health
Boehringer Ingelheim
Colorcon
Medtronic
Express Scripts
McKesson
Harvard Business School
Novartis

Generated: September 26, 2017

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bimatoprost and what is the scope of bimatoprost freedom to operate?

Bimatoprost
is the generic ingredient in three branded drugs marketed by Sandoz Inc, Apotex Inc, Allergan, and Lupin Ltd, and is included in eight NDAs. There are twenty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has sixty-three patent family members in twenty-one countries.

There are twelve drug master file entries for bimatoprost. Five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: bimatoprost

Tradenames:3
Patents:23
Applicants:4
NDAs:8
Drug Master File Entries: see list12
Suppliers / Packagers: see list5
Bulk Api Vendors: see list35
Clinical Trials: see list112
Patent Applications: see list2,858
Therapeutic Class:Ophthalmic Agents
Drug Prices:see low prices
DailyMed Link:bimatoprost at DailyMed

Pharmacology for Ingredient: bimatoprost

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Tentative approvals for BIMATOPROST

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.03SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.01%SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.01%SOLUTION;OPHTHALMIC
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Sandoz Inc
BIMATOPROST
bimatoprost
SOLUTION/DROPS;TOPICAL202719-001Apr 19, 2016ATRXNoNo► Subscribe► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: bimatoprost

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,388,029Compositions and methods for treating hair loss using non-naturally occurring prostaglandins► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
8,298,518Method of enhancing hair growth► Subscribe
7,351,404Method of enhancing hair growth► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: bimatoprost

Country Document Number Estimated Expiration
Canada2585691► Subscribe
Australia2012261499► Subscribe
Canada2475106► Subscribe
Israel185744► Subscribe
Australia2008203212► Subscribe
Denmark1753434► Subscribe
China100384425► Subscribe
Norway20074390► Subscribe
Japan2003528899► Subscribe
World Intellectual Property Organization (WIPO)2010102078► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BIMATOPROST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/035United Kingdom► SubscribePRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
C0033France► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Healthtrust
US Department of Justice
Farmers Insurance
US Army
Cipla
Johnson and Johnson
Federal Trade Commission
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot